A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
| Status: | Completed |
|---|---|
| Conditions: | Other Indications, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2016 |
| Start Date: | July 2012 |
| End Date: | October 2013 |
A Multicenter, Open Label, Phase 1B Study of Escalating Doses of RO5045337 Administered Orally, With Cytarabine Administered A) Subcutaneously, or B) Intravenously, in Patients With Acute Myelogenous Leukemia (AML)
This multi-center, open-label, Phase 1b study will evaluate the safety, pharmacokinetics and
efficacy of RO5045337 in combination with cytarabine in patients with acute myelogenous
leukemia. In Arm A, cohorts of previously untreated patients deemed unsuitable for standard
induction therapy will receive escalating oral doses of RO5045377 and cytarabine 20 mg/m2
subcutaneously daily for Days 1 to 10 of each 28-day cycle. In Arm B, cohorts of patients
who have relapsed or are refractory after at least one cytarabine/anthracycline containing
regimen will receive escalating oral doses of RO5045377 on Days 1 to 5 and cytarabine 1
gm/m2 intravenously on Days 1 to 6 of each 28-day cycle. Patients will receive up to 4
cycles of therapy, patients in Arm A who achieve hematologic response may continue
additional cycles until disease progression.
efficacy of RO5045337 in combination with cytarabine in patients with acute myelogenous
leukemia. In Arm A, cohorts of previously untreated patients deemed unsuitable for standard
induction therapy will receive escalating oral doses of RO5045377 and cytarabine 20 mg/m2
subcutaneously daily for Days 1 to 10 of each 28-day cycle. In Arm B, cohorts of patients
who have relapsed or are refractory after at least one cytarabine/anthracycline containing
regimen will receive escalating oral doses of RO5045377 on Days 1 to 5 and cytarabine 1
gm/m2 intravenously on Days 1 to 6 of each 28-day cycle. Patients will receive up to 4
cycles of therapy, patients in Arm A who achieve hematologic response may continue
additional cycles until disease progression.
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Patients with histologically or cytologically documented acute myelogenous leukemia
appropriate for cytarabine therapy including:
- Arm A: Patients who have not received prior standard induction chemotherapy,
considered unsuitable for standard induction therapy
- Arm B: Patients who have failed their 1st or greater line of standard induction
chemotherapy (primary refractory) or patients who originally achieved a complete
response but are currently in first or greater relapse
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- All non-hematological adverse events of any prior chemotherapy, surgery, or
radiotherapy must have resolved to NCI-CTC AE Grade
- Adequate hepatic and renal function
- Patient must be willing to submit the blood sampling and bone marrow sampling for PK
and PD analyses and exploratory biomarkers
Exclusion Criteria:
- History of allergic or toxic reactions attributed to cytarabine or a history of
allergic reactions to components of the formulated product
- Current evidence of CNS leukemia
- Any severe and/or uncontrolled medical condition or other conditions that could
affect the participation in the study
- Pregnant or breastfeeding women
- HIV-positive patients receiving combination anti-retroviral therapy
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials